Advice
Following a full submission
erdosteine (Erdotin®) is not recommended for use within NHS Scotland as an expectorant for the symptomatic treatment of acute exacerbations of chronic bronchitis in adults.
Evidence for the clinical efficacy of erdosteine is limited and was obtained from studies that do not reflect current practice for the management of chronic obstructive pulmonary disease (COPD) in NHS Scotland. The manufacturer did not present a sufficiently robust clinical or economic case for erdosteine to gain acceptance by SMC.
Download detailed advice42KB (PDF)
Medicine details
- Medicine name:
- erdosteine 300mg capsules (Erdotin)
- SMC ID:
- 415/07
- Indication:
- Chronic Bronchitis in adults
- Pharmaceutical company
- Edmond Pharma Sr.I/Galen Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 12 November 2007